Stocks · Health care · Biological Products, (No Diagnostic Substances)

Pelthos Therapeutics Inc.

PTHS Clue Score29
United States Fiscal year ends December CIK 0001919246 Results filed 13 Aug 2026

What the insiders did Net buying

By person

8 insiders · 39 transactions

There is no salary here to measure against. Pelthos Therapeutics Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Todd C Davis
Director
$999.98K (2)
—
+$999.98K
1,575,834
$33.09M
+14,601%
Ezra M Friedberg
Director
—
$325.79K (11)
−$325.79K
232,556
$4.88M
+61.5%
Peter Greenleaf
Director
—
$54.37K (5) scheduled
−$54.37K
23,087
$484.83K
−9.4%
Matthew Pauls
Director
—
$53.51K (5) scheduled
−$53.51K
13,578
$285.14K
−8.6%
Knuettel Francis II
CFO, Treas & Secty
$16.00K (4)
$40.26K (1)
−$24.27K
30,841
$647.66K
−21.1%
Richard Malamut
Director
$9.82K (1)
$12.34K (2) scheduled
−$2.52K
118,987
$2.50M
+9.0%
Ligand Pharmaceuticals Inc entity
Director
—
—
—
1,500,000
$31.50M
—
Andrew J. Einhorn
Director
—
—
—
12,000
$252.00K
—

No percentages here. This company's share count has moved by a factor of 2.0 over the window, from 3,042,143 to 6,103,813 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.